Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.

• Some investors are considering whether BioMarin Pharmaceutical’s current share price reflects its underlying value, or if the market may be overlooking certain factors.

• The stock last closed at US$54.53, with returns of a 1.7% decline over 7 days, 6.8% decline over 30 days, 8.3% decline year to date, 4.0% decline over 1 year, 44.9% decline over 3 years and 31.3% decline over 5 years.

• Recent coverage has focused on BioMarin’s role in the biotechnology space and how sentiment around its pipeline and commercial portfolio relates to the share price. This context helps explain why some investors are reassessing the…